COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00123578
Recruitment Status : Withdrawn (Unable to recruit adaquate number of GHB dependent subjects)
First Posted : July 25, 2005
Last Update Posted : May 12, 2016
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Karen Miotto, University of California, Los Angeles

Brief Summary:
Gamma hydroxybutyrate (GHB) is a powerful central nervous system depressant. The number of individuals seeking treatment for GHB abuse has been steadily increasing in the United States. Currently, lorazepam and pentobarbital are two medications used to treat individuals who experience GHB-withdrawal symptoms. The purpose of this study is to describe the signs and symptoms of GHB withdrawal and to identify predictors of withdrawal severity. The study will also evaluate the safety and effectiveness of treatment with lorazepam versus pentobarbital for GHB detoxification.

Condition or disease Intervention/treatment Phase
Substance-Related Disorders Drug: Lorazepam Drug: Pentobarbital Phase 1 Phase 2

Detailed Description:

GHB and GHB precursors such as 1,4-butanediol and gamma-butylrolactone (GBL) have become popular drugs of abuse. In cases of severe withdrawal, delirium, confusion, hallucinations, and agitation can occur. There has been a sharp rise in the number of GHB related emergency room visits over the past few years, yet little is known about the effective treatment of GHB withdrawal and dependence. The purpose of this study is to describe the signs and symptoms of GHB withdrawal, identify predictors of withdrawal severity, and evaluate the safety and effectiveness of treatment for GHB detoxification. There will be compensation for screening assessments.

The study includes two phases. The open-label Phase 1 will aim to determine the safety of lorazepam for the treatment of mild GHB withdrawal. Participants who progress into moderate or severe withdrawal will enter the controlled Phase 2. In Phase 2, participants will be randomly assigned to receive either lorazepam or pentobarbital in order to determine which drug is more effective in treating GHB withdrawal.

The study will consist of 1 to 2 outpatient screening visits, followed by up to 15 days of inpatient detoxification treatment and assessment. After hospital discharge from inpatient treatment, measures of protracted GHB withdrawal and psychiatric symptoms will be obtained on an outpatient weekly basis for 8 weeks. Repeat measures of cognitive functioning will be obtained at baseline, termination of treatment, and at 30, 60, and 90-day follow-up intervals in order to assess long-term neurocognitive effects of GHB withdrawal and use.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: GHB: Effects, Withdrawal and Treatment
Study Start Date : August 2004
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Abuse

Arm Intervention/treatment
Experimental: Lorazepam
Lorazepam for the treatment of mild GHB withdrawal.
Drug: Lorazepam
Other Name: Ativan

Active Comparator: Pentobarbital
Pentobarbital for the treatment of mild GHB withdrawal.
Drug: Pentobarbital
Other Name: Nembuta

Primary Outcome Measures :
  1. Subjective withdrawl symptoms measures using CIWA scale [ Time Frame: daily during medical administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets DSM-IV criteria for GHB dependence
  • Self-reported as GHB dependent with current daily use of GHB
  • Use of GHB for at least 20 consecutive days prior to enrollment
  • Desire to stop GHB use
  • Availability of a friend or family member to act as a collateral informant
  • Speaks and understands English

Exclusion Criteria:

  • Females who are pregnant, breastfeeding, or do not agree to use adequate forms of contraception
  • History of seizures
  • A baseline EEG of clinical concern that requires inpatient ICU detoxification
  • Any anticonvulsant therapy during the 3 years prior to enrollment
  • Pancreatic disease, such as insulin-dependent diabetes
  • Liver disease that requires medication or medical treatment
  • Gastrointestinal or kidney disease that might significantly impair absorption, metabolism, or excretion of study drug, or might require medication or medical treatment
  • Asthma, hives, angioedema, or similar condition
  • Acute intermittent porphyria or porphyria variegata
  • Neurological or psychiatric disorders, including psychosis, bipolar disorder, or other disorders that require treatment or might make study compliance difficult (assessed by the Structured Clinical Interview for DSM-IV-TR)
  • Positive tuberculosis (PPD) skin test with a clinical history and chest X-ray indicative of active tuberculosis (individuals with a positive PPD test and a negative chest X-ray, who are not symptomatic for tuberculosis and do not require antituberculosis therapy, will be eligible to participate)
  • Clinically significant abnormal baseline EKG
  • Requirement for any of the following medications currently or within the 4 weeks prior to enrollment: psychotropics (including sedatives/hypnotics, antidepressants, neuroleptics), prescription analgesics, anticonvulsants, antihypertensives, antiarrhythmics, or antiretroviral medications
  • Nicotine dependent participants will be given nicotine patch therapy for the duration of the study; participants who refuse nicotine patch therapy will continue in the study as determined by the hospital smoking and standard of care regulations
  • Meets DSM-IV criteria for dependence on any psychoactive substance other than GHB, caffeine, or nicotine
  • Symptomatic HIV infection
  • Alcohol breath test greater than .05 ppm at time of hospital admission

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00123578

Layout table for location information
United States, California
Los Angeles, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Karen Miotto, M.D. University of California, Los Angeles
Layout table for additonal information
Responsible Party: Karen Miotto, Clinical Professor, University of California, Los Angeles Identifier: NCT00123578    
Other Study ID Numbers: NIDA-14291-1
K23DA014291 ( U.S. NIH Grant/Contract )
First Posted: July 25, 2005    Key Record Dates
Last Update Posted: May 12, 2016
Last Verified: May 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia